3B Blackbio DX Ltd
3B Blackbio DX Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 investor presentation: what the company reported on revenue, margins and projects.
Based on 3B Blackbio DX Ltd's Q4 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q4 FY 2024-25 revenue: INR 2,249.51 Lakh; Q4 FY 2023-24 revenue: INR 2,299.80 Lakh (slight YoY decrease). EBITDA for Q4 2024-25: INR 1,253.91 Lakh - Year-on-year change: Decrease from INR 1,372.90 Lakh (Q4 2023-24) - Profit After Tax (PAT) for Q4 2024-25: INR 803.55 Lakh - Year-on-year change: Decrease from INR 879.03 Lakh (Q4 2023-24) - Revenue from Operations for Q4 2024-25: INR 2,249.51 Lakh - Year-on-year change: Slight decrease from INR 2,299.80 Lakh (Q4 2023-24) - Operating Margin: Not explicitly stated as a percentage; however, EBITDA and PAT margins can be roughly inferred but no explicit margin percentages or outlook given.
From 3B Blackbio DX Ltd's Q4 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q4 FY 2024-25 revenue: INR 2,249.51 Lakh; Q4 FY 2023-24 revenue: INR 2,299.80 Lakh (slight YoY decrease).
- Consolidated sales in Q4 2024-25: INR 1,947.96 Lakh vs INR 1,906.48 Lakh in Q4 2023-24 (including TRUPCR Europe Limited sales of INR 187.18 Lakh).
- Export sales Q4 2024-25: INR 410.40 Lakh vs INR 290.15 Lakh in Q4 2023-24 (substantial increase).
- UK subsidiary (TRUPCR Europe Limited) revenue FY 2024-25: GBP 1,287,580, a 94% increase over FY 2023-24 GBP 664,059. Projected 20-25% growth in FY 2025-26.
2 more points management made on revenue & sales performance
Profitability & Margins
See what 3B Blackbio DX Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company is continuously investing in building additional manufacturing and R&D facilities/capacities to support existing business verticals (Page 41).
- New products are being designed and launched to meet increasing market needs and maintain growth momentum (Page 41).
- No specific amounts, statuses, or timeline details for capex/expansion projects are provided explicitly in the presentation.
- A joint venture in Manchester, UK, may receive funding deployment depending on need (Page 41).
2 more points management made on capital expenditure plans
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what 3B Blackbio DX Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
3B Blackbio DX Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹50 Cr, net profit ₹22 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What 3B Blackbio DX Ltd's management said in earlier quarters
Others in Healthcare Services this season
- Apollo Hospitals Enterprise Ltd (Q4 FY25)
. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Shalby (Q4 FY25)
Implant business is in high-growth mode: 4x growth in Indonesia, 35-40% growth in U.S., and 2.5x growth in India reported last year. Key concall takeaways from…
- Suraksha Diagno. (Q4 FY25)
Volume of tests conducted has been growing at around 10% year-on-year between FY '24 and FY '25. Key concall takeaways from Suraksha Diagnostic Ltd's Q4 FY25…
- Narayana Hrudayalaya Ltd (Q4 FY25)
Capex is split between regular maintenance/replacement (~INR 300 crores) and new greenfield/brownfield capacity (~INR 450 crores) with some variability based…
Frequently Asked Questions
What were 3B Blackbio DX Ltd Q4 FY25 results?
Q4 FY 2024-25 revenue: INR 2,249.51 Lakh; Q4 FY 2023-24 revenue: INR 2,299.80 Lakh (slight YoY decrease). EBITDA for Q4 2024-25: INR 1,253.91 Lakh - Year-on-year change: Decrease from INR 1,372.90 Lakh (Q4 2023-24) - Profit After Tax (PAT) for Q4 2024-25: INR 803.55 Lakh - Year-on-year change: Decrease from INR 879.03 Lakh (Q4 2023-24) - Revenue from Operations for Q4 2024-25: INR 2,249.51 Lakh - Year-on-year change: Slight decrease from INR 2,299.80 Lakh (Q4 2023-24) - Operating Margin: Not explicitly stated as a percentage; however, EBITDA and PAT margins can be roughly inferred but no explicit margin percentages or outlook given.
What is 3B Blackbio DX Ltd share price analysis?
3B Blackbio DX Ltd currently shows a neutral. The stock trades at a P/E of 20.4 with a market cap of ₹1,132 Cr. Investors should review the full earnings analysis for detailed insights.
Is 3B Blackbio DX Ltd planning capital expenditure?
The company is continuously investing in building additional manufacturing and R&D facilities/capacities to support existing business verticals (Page 41). - New products are being designed and launched to meet increasing market needs and maintain growth momentum (Page 41). - No specific amounts, statuses, or timeline details for capex/expansion projects are provided explicitly in the presentation. - A joint venture in Manchester, UK, may receive funding deployment depending on need (Page 41). - No mention of new plants or major greenfield projects. - Expansion focus appears on enhancing current manufacturing/R&D capacities rather than new plants (Page 41). Summary: The presentation highlights ongoing capacity and R&D facility expansions without quantifying capex or providing detailed timelines/status.
Keep 3B Blackbio DX Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.